- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06069648
Effects of Decision Aids on the Participation of South Asian Women in Cervical Cancer Screening
Effects of Decision Aids on the Participation of South Asian Women in Cervical Cancer Screening: A Randomised Controlled Trial
Objectives: To examine the effects of linguistically appropriate decision aids on decisional conflicts, risk perception, clarity of values, screening decisions and screening uptake among South Asian women in Hong Kong Design and subjects: A randomised controlled trial. A sample of 270 South Asian women aged 25-64 will be recruited to one of the two intervention groups or control group.
Instruments: A survey will be conducted to collect data on the variables of concern (decisional conflicts, risk perception, clarity of values, screening decision and screening uptake).
Interventions: Ethnically match community health workers (CHWs) will deliver the printed or mobile application decision aids to intervention group participants and briefly explain how to use the decision aid. The participants will choose a time and place of their convenience to read the decision aid. The participants will be contacted by CHWs within 2 weeks and asked if they have experienced any problems. Navigation assistance will be given as requested.
Main outcome measures: Decisional conflicts, risk perception, clarity of values, screening decision and uptake.
Data analysis: The repeated-measure outcomes of risk perception, clarity of values, decisional conflicts and screening decision will be compared between the three groups while adjusting for the stratifying variable (ethnicity) using a generalised estimating equation model, and a multivariable logistic regression with adjustment for ethnicity will be used to compare the screening uptake of the three groups.
Expected results: The decision aid will clarify the participants' values and help them to make screening decisions and increase the uptake.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dorothy Chan
- Phone Number: +85239438165
- Email: dorothycns@cuhk.edu.hk
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Indian, Pakistani or Nepalese;
- aged 25 to 64;
- no history of cervical cancer or total hysterectomy;
- have a history of sexual activity;
- cannot understand Chinese but can read or communicate in English, Hindi, Urdu or Nepali;
- have not had a Pap/HPV test in the past 3 years;
- have and are willing to use a smartphone in this intervention.
Exclusion Criteria:
- NA
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: control
factsheet about healthy living
|
a leaflet containing information about healthy lifestyles
|
|
Experimental: printed decision aid
receive printed decision aid
|
a booklet form of screening decision aid containing information of cervical cancer screening options
|
|
Experimental: mobile decision aid
receive mobile decision aid
|
a mobile app format of screening decision aid containing information of cervical cancer screening options
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
decisional conflict
Time Frame: baseline and 2 weeks after intervention
|
16-item Decisional Conflict Scale will be used to measure decisional conflict.
The scale consists of five subscales: informed subscale, values clarity subscale, support subscale, uncertainty subscale and effective decision subscale.
The scores will be converted to a 0-100 scale, giving a possible range of 0 (no decisional conflict) to 100 (extremely high decisional conflict).
A score of 25 or below indicates that a person has low decisional conflict, and a score of 37.5 and above indicates that a person has decisional delay.
|
baseline and 2 weeks after intervention
|
|
cervical cancer screening uptake
Time Frame: 3 months after intervention
|
The participants will be asked 'Have you undergone cervical cancer screening in the past 3 months?
|
3 months after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
risk perception
Time Frame: baseline and 2 weeks after intervention
|
One question will be used to assess the participants' perceptions of their risk of cancer.
Women will be asked to rate their risk of cervical cancer as low, moderate or high.
|
baseline and 2 weeks after intervention
|
|
screening decision: choice predisposition
Time Frame: baseline and 2 weeks after intervention
|
Choice predisposition assesses a person's leaning towards an option and is rated on a 15-point scale that ranges from 1 (leaning towards 'yes') to 15 (leaning towards 'no').
|
baseline and 2 weeks after intervention
|
|
screening decision: choice question
Time Frame: baseline and 2 weeks after intervention
|
The choice question asks about the screening decision and a question about the use of a screening option (Pap test/HPV testing).
It is assessed using a 'no/yes/unsure' format.
|
baseline and 2 weeks after intervention
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
Other Study ID Numbers
- HMRFSADA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Tata Memorial HospitalMahidol University; Juntendo University; Gunma University; Chiang Mai University...RecruitingStage IIA Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO 2018 | Stage IIIB Cervical Cancer FIGO 2018 | Stage IVA Cervical Cancer FIGO 2018 | Stage IB Cervical Cancer FIGO 2018India, Japan, Thailand
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
Qi ZhouNot yet recruitingCervical Cancer Recurrent | Cervical Cancer Metastatic
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingCervical Cancer Recurrent | Cervical Cancer Metastatic
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingCervical Large Cell Neuroendocrine Carcinoma | Cervical Neuroendocrine Carcinoma | Cervical Small Cell Carcinoma | Cervical Undifferentiated Carcinoma | Stage I Cervical Cancer AJCC v8 | Stage IA Cervical Cancer AJCC v8 | Stage IA1 Cervical Cancer AJCC v8 | Stage IA2 Cervical Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
Clinical Trials on a leaftlet
-
Johnson & Johnson Vision Care, Inc.CompletedCorneal Infiltrative Events | Corneal InflammationUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
CooperVision, Inc.Completed
-
CooperVision International Limited (CVIL)Completed
-
Bausch & Lomb IncorporatedCompleted
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
University of OttawaCompletedBorderline Personality Disorder | Deliberate Self Harm